1.
Cancer Cell
; 41(5): 821-823, 2023 05 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37116490
RESUMO
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.